Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural basis of Fabry disease.

Scott C Garman1, David N Garboczi

  • 1Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, 12441 Parklawn Drive, Rockville, MD 20852, USA.garman@alpha.niaid.nih.gov

Molecular Genetics and Metabolism
|October 3, 2002
PubMed
Summary

Fabry disease, a lysosomal storage disorder, stems from alpha-galactosidase (alpha-GAL) deficiency. This study maps mutations, revealing active site and folding defects, with the active site being a hotspot for Fabry disease mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural basis of double-stranded RNA recognition by the J2 monoclonal antibody.

Nature communications·2025
Same author

A domain-swapped CaMKII conformation facilitates linker-mediated allosteric regulation.

Nature communications·2025
Same author

The 2.3 Å Structure of A21, a Protein Component of the Conserved Poxvirus Entry-Fusion Complex.

bioRxiv : the preprint server for biology·2025
Same author

Specificity and mechanism of the double-stranded RNA-specific J2 monoclonal antibody.

bioRxiv : the preprint server for biology·2025
Same author

Maturation of Lysosomal α-Galactosidase A and Implications for Fabry Disease.

Nephron·2025
Same author

Chemokines kill bacteria without triggering antimicrobial resistance by binding anionic phospholipids.

Science advances·2025

Area of Science:

  • Biochemistry
  • Genetics
  • Structural Biology

Background:

  • Fabry disease is a lysosomal storage disorder resulting from alpha-galactosidase (alpha-GAL) deficiency.
  • Understanding the molecular basis of Fabry disease is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the structural locations and types of mutations causing Fabry disease.
  • To identify mutation hotspots within the alpha-GAL enzyme.

Main Methods:

  • Collected and mapped over 190 reported point and stop mutations for human alpha-GAL.
  • Utilized the X-ray structure of alpha-N-acetylgalactosaminidase (alpha-NAGAL) to model human alpha-GAL.
  • Analyzed mutation frequencies around alpha-GAL residues.

Related Experiment Videos

Main Results:

  • Identified two primary classes of alpha-GAL defects: active site and folding mutations.
  • Active site mutations directly impair enzyme function without major structural changes.
  • Folding mutations destabilize alpha-GAL by disrupting its hydrophobic core.
  • The enzyme's active site was identified as a mutation hotspot in Fabry disease.

Conclusions:

  • The study elucidates the structural basis of Fabry disease-causing mutations.
  • Findings provide insights into enzyme instability and dysfunction in lysosomal storage diseases.
  • This research may pave the way for novel therapeutic strategies for Fabry disease and other lysosomal storage disorders.